ONC (BeOne Medicines) Institutional Ownership: 33.56% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
77 GF Score
Price $316.50
GF Value $369.44
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Institutional Ownership?

BeOne Medicines ONC +1.68% 77 Institutional Ownership is 33.56% as of Jul. 16, 2026. GuruFocus rates ONC with a GF Score™ of 77/100 and a GF Value™ of $369.44 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeOne Medicines's institutional ownership is 33.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeOne Medicines's Insider Ownership is 0.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeOne Medicines's Float Percentage Of Total Shares Outstanding is 68.42%.

BeOne Medicines Institutional Ownership Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Institutional Ownership Chart

BeOne Medicines Historical Data

The historical data trend for BeOne Medicines can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 26.09 24.05 24.25 22.72 22.77 22.81 23.27 23.14 22.47 22.40
ONC
77GF Score
BeOne Medicines Ltd ONC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 33.56% mean?
BeOne Medicines (ONC) has a Institutional Ownership of 33.56% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Institutional Ownership too high?
BeOne Medicines' current Institutional Ownership is 33.56%. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Institutional Ownership compare to MRNA and RPRX?
BeOne Medicines' Institutional Ownership of 33.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Institutional Ownership is 33.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $369.44, compared to a current price of $316.50 — trading 14.3% below its estimated fair value. The current Institutional Ownership is 33.56%. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Institutional Ownership is 33.56% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $316.50 is trading 14.3% below its estimated GF Value™ of $369.44. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Institutional Ownership: 33.56%
  • GF Value™: $369.44 vs. price of $316.50 (14.3% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score

Get the complete analysis for ONC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$316.50
Price
$369.44
GF Value